ICER re­vis­es sick­le cell gene ther­a­py re­port, preps to dig in­to what CMS ne­go­ti­a­tions might look like

The Boston-based In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, a drug price watch­dog, has re­vised its re­port on sick­le cell gene ther­a­pies and is plan­ning a new re­port this Sep­tem­ber that will eval­u­ate how CMS might ne­go­ti­ate the prices for two block­busters: Bris­tol My­ers Squibb’s Eliquis (apix­a­ban) and Bay­er’s Xarel­to (ri­varox­a­ban).

The two drugs are like­ly to be se­lect­ed for the first year of ne­go­ti­a­tions as part of the In­fla­tion Re­duc­tion Act, along­side oth­ers like Ab­b­Vie’s Im­bru­vi­ca.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER